Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Artiva Biotherapeutics, Inc. has received a consensus rating of "Moderate Buy" from five research firms, with an average price target of $17.00 based on recent reports.
• CEO Fred Aslan sold 25,500 shares at an average price of $2.73, reducing his ownership by 6.19% while insiders hold 21.40% of the company's stock.
• Artiva reported a quarterly loss of ($0.87) EPS, missing estimates, and is projected to post ($4.95 EPS) for the current year.

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the five research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $17.00.

A number of brokerages have weighed in on ARTV. HC Wainwright raised Artiva Biotherapeutics to a "buy" rating and set a $12.00 target price on the stock in a report on Wednesday, June 11th. Weiss Ratings reissued a "sell (e+)" rating on shares of Artiva Biotherapeutics in a research report on Saturday, September 27th.

Insider Buying and Selling at Artiva Biotherapeutics

In other news, CEO Fred Aslan sold 25,500 shares of the business's stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $2.73, for a total value of $69,615.00. Following the transaction, the chief executive officer owned 386,693 shares in the company, valued at $1,055,671.89. The trade was a 6.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 21.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Ground Swell Capital LLC purchased a new position in Artiva Biotherapeutics in the second quarter worth $38,000. Y Intercept Hong Kong Ltd bought a new position in Artiva Biotherapeutics in the second quarter worth about $48,000. Bridgeway Capital Management LLC bought a new position in Artiva Biotherapeutics in the second quarter worth about $53,000. Qube Research & Technologies Ltd bought a new position in shares of Artiva Biotherapeutics during the second quarter valued at approximately $58,000. Finally, Jane Street Group LLC bought a new position in shares of Artiva Biotherapeutics during the second quarter valued at approximately $67,000.

Artiva Biotherapeutics Stock Performance

NASDAQ:ARTV remained flat at $2.95 on Friday. The company's stock had a trading volume of 44,873 shares, compared to its average volume of 114,656. The stock's fifty day moving average price is $2.85 and its 200-day moving average price is $2.47. Artiva Biotherapeutics has a 1 year low of $1.47 and a 1 year high of $16.87.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.03). Sell-side analysts forecast that Artiva Biotherapeutics will post -4.95 earnings per share for the current year.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.